How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

摘要: Although multiple myeloma (MM) remains incurable, the introduction of novel agents has improved clinical outcomes dramatically over past 15 years. Response rates have risen from ∼30% with single to up 90% combination therapies. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, proteasome inhibitor bortezomib, form foundations for treatment relapsed and/or refractory MM (RRMM). Newer agents, such as IMiD pomalidomide, histone deacetylase panobinostat inhibitors carfilzomib ixazomib, well monoclonal antibodies daratumumab elotuzumab, further overall response in these patients. Importantly, increased been observed heavily pretreated availability highly effective tolerable may offer alternative strategies those who are unsuitable thalidomide, lenalidomide or bortezomib. Improving tolerability regimens lengthening progression‐free intervals shown significantly improve health-related quality life patients living RRMM.